RT @Cochrane_DE: Elon Musk spricht in einem aktuellem Interview über die Einnahme von Ketamin gegen depressive Zustände. Das SMC UK hat daz…
RT @Cochrane_DE: Elon Musk spricht in einem aktuellem Interview über die Einnahme von Ketamin gegen depressive Zustände. Das SMC UK hat daz…
Elon Musk spricht in einem aktuellem Interview über die Einnahme von Ketamin gegen depressive Zustände. Das SMC UK hat dazu Expert*innen befragt. Und wir die @CochraneLibrary, die dazu diesen Review von 2021 ausspuckt: https://t.co/sg9mgsL5TB #ElonMusk #de
@Dag_Torp Antidep. har liten/moderat effekt (SMD≈0,30) og moderat evidensgrad. https://t.co/2zY7CLz1u3 Esketamin har tilsvarende effekt og evidensgrad. Ketamin har et høyere effektestimat, men evidensen er av veldig lav til lav kvalitet. https://t.co/DOqyq
RT @tetisu: A medicação que o Incel de Pirú pequeno anda advogando ainda não tem dados robustos que comprovem a sua eficácia. Mas quem diss…
A medicação que o Incel de Pirú pequeno anda advogando ainda não tem dados robustos que comprovem a sua eficácia. Mas quem disse que as pessoas querem evidências? A maioria quer é seguir um guru. E não só seguir, mas encher o bolso dele de dinheiro. https
@drmikehart @VPrasadMDMPH Effect size estimates of ketamine should be interpreted with caution given the very low‐ to low-certainty evidence. https://t.co/DOqyqg9UhV Furthermore, most systematic reviews of ketamine are of critically low quality. https://t.
Esketamine has an effect size on par with antidepressants and is supported by moderate certainty evidence. Ketamine has somewhat larger effect size (SMD≈0.40~0.90; but wide 95%CI), but is only supported by very low to low certainty evidence. https://t.co/d
@HFMarthinussen @KristianGunder @BenHolen Jeg tror du med fordel kan lese trådstarten på nytt. Jeg påpeker ingenting annet enn at evidensen er for dårlig til å ta i bruk ketamin for depresjon utenfor kliniske studier med henvisning til en nylig SR/MA fra @
RT @Utretteligegro: Det er trist at vi har svært mange pasienter som må sette seg på flyet for hver behandling. At vi deler ut medisin som…
RT @Utretteligegro: Det er trist at vi har svært mange pasienter som må sette seg på flyet for hver behandling. At vi deler ut medisin som…
Det er trist at vi har svært mange pasienter som må sette seg på flyet for hver behandling. At vi deler ut medisin som har så dårlig effekt at pasienter føler seg behandlingsresistent. Vi trenger Ketamin klinikker i alle byer, tilgjengelig for de som treng
RT @joarhalvorsen: Hvorfor må pasientene vente på ketamin? https://t.co/Lo402eyUqB Fordi evidensen er for dårlig til at ketamin for depress…
RT @joarhalvorsen: Hvorfor må pasientene vente på ketamin? https://t.co/Lo402eyUqB Fordi evidensen er for dårlig til at ketamin for depress…
RT @joarhalvorsen: Hvorfor må pasientene vente på ketamin? https://t.co/Lo402eyUqB Fordi evidensen er for dårlig til at ketamin for depress…
RT @joarhalvorsen: Hvorfor må pasientene vente på ketamin? https://t.co/Lo402eyUqB Fordi evidensen er for dårlig til at ketamin for depress…
Hvorfor må pasientene vente på ketamin? https://t.co/Lo402eyUqB Fordi evidensen er for dårlig til at ketamin for depressive lidelser bør tas i bruk utenfor kliniske studier. https://t.co/DOqyqg9UhV
@awaisaftab @RPurssey @eturnermd1 Puh, a lot of COIs. I rather would recommend the Cochrane review https://t.co/8NGgTqkX0k The short-term efficacy of ketamine is impressive (but also uncertainty) and I wonder about the harm/benefit ratio in comparison to
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
RT @PloederlM: 1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in…
1/ Two systematic reviews about (Es)Ketamine. One Cochrane review: https://t.co/8NGgTq3m8M "No differences were found in suicidality at any time point, suggesting that ketamine is not an effective treatment for suicidality over placebo" (Same for Esketa
RT @joarhalvorsen: Recent @cochranecollab review of the trials for ketamine as treatment for adults with unipolar major depressive disorder…
..ketamine & esketamine may be more efficacious than placebo @ 24h. How..findings translate into clinical practice..not entirely clear. Long term non‐inf RCTs..& rigorous real‐world monitoring needed to establish comprehensive data on safety &
Recent @cochranecollab review of the trials for ketamine as treatment for adults with unipolar major depressive disorder consistently evaluating the evidence as being of «very low certainty» and questioning the clinical utility. https://t.co/DOqyqg9UhV
RT @beccalouisedean: Read the full reviews here ⬇️ Unipolar depression: https://t.co/5GpxZS9yAj Bipolar depression: https://t.co/R0eWNjCSu0
RT @beccalouisedean: Read the full reviews here ⬇️ Unipolar depression: https://t.co/5GpxZS9yAj Bipolar depression: https://t.co/R0eWNjCSu0
Read the full reviews here ⬇️ Unipolar depression: https://t.co/5GpxZS9yAj Bipolar depression: https://t.co/R0eWNjCSu0
Ketamina y depresión https://t.co/AvkMfKUyhm
MA: ketamine results in an increase on response and remission vs PLA at 24 hours in MDD (OR=3.94; 1.54-10.10) and in reduction of depression rating scale (SMD= -0.87; -1.26 to -0.48) without difference in dropping out for any reason (OR=1.25; 0.19-8.28) ht
RT @CochraneJapan: 成人のうつ病に対するケタミンなどのグルタミン酸受容体モジュレーターの効果 https://t.co/k6cHx7STw3
RT @alfonso_casi: Ketamina y otros moduladores de los receptores de glutamato para adultos con trastorno depresivo mayor unipolar: La ketam…
RT @alfonso_casi: Ketamina y otros moduladores de los receptores de glutamato para adultos con trastorno depresivo mayor unipolar: La ketam…
Ketamina y otros moduladores de los receptores de glutamato para adultos con trastorno depresivo mayor unipolar: La ketamina y lsketamina podrían ser más eficaces que el placebo a las 24 horas... https://t.co/rXjnBIWx8t https://t.co/B3j9IqwIAK
RT @CochraneJapan: 成人のうつ病に対するケタミンなどのグルタミン酸受容体モジュレーターの効果 https://t.co/k6cHx7STw3
RT @CochraneJapan: 成人のうつ病に対するケタミンなどのグルタミン酸受容体モジュレーターの効果 https://t.co/k6cHx7STw3
成人のうつ病に対するケタミンなどのグルタミン酸受容体モジュレーターの効果 https://t.co/k6cHx7STw3
RT @MichaelHaichin: Cochrane review of ketamine and other glutamate receptor modulators for depression https://t.co/aTQHvbQ3B1 https://t.co…
RT @MichaelHaichin: Cochrane review of ketamine and other glutamate receptor modulators for depression https://t.co/aTQHvbQ3B1 https://t.co…
RT @MichaelHaichin: Cochrane review of ketamine and other glutamate receptor modulators for depression https://t.co/aTQHvbQ3B1 https://t.co…
Cochrane review of ketamine and other glutamate receptor modulators for depression https://t.co/aTQHvbQ3B1 https://t.co/LWitGMXi0g
RT @PloederlM: New Cochrane systematic review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar maj…
RT @PloederlM: New Cochrane systematic review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar maj…
RT @PloederlM: New Cochrane systematic review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar maj…
RT @PloederlM: New Cochrane systematic review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar maj…
New Cochrane systematic review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder" https://t.co/8NGgTq3m8M @CVolkmannMD @NaudetFlorian @IoanaA_Cristea @joannamoncrieff
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder - Dean, RL - 2021 | Cochrane Library https://t.co/4bzLOp2JMg